

PIP Partnership Contributions (2012 - 2026)

status as at 31 March 2026

Contributors	Total Contributions (US\$)
Sanofi Pasteur	101,538,009
Glaxosmithkline (GSK)	76,795,708
Hoffmann - La Roche and Co. Ltd.	66,587,934
Seqirus	39,190,667
Novartis	15,292,743
Medimmune	12,788,326
K M Biologics Co. Ltd. (ex-Kaketsuken)	7,230,564
Research Foundation for Microbial Disease of Osaka University (BIKEN)	6,878,268
Denka Seiken Co. Ltd.	5,050,328
Daiichi Sankyo Vaccine Co. Ltd. (ex - Kitasato Daiichi)	3,981,715
G C Pharma (Ex-Green Cross Corporation)	3,674,136
Instituto Butantan	3,344,874
CSL Limited	2,667,745
Sinovac Biotech Ltd.	2,069,355
Shanghai Institute of Biological Products Co., Ltd.	1,378,073
Hualan Biological Bacterin Inc.	891,234
Fluart Innovative Vaccines Ltd. (ex-Omninvest Vaccine Manufacturing Ltd.)	844,411
S K Bioscience	734,305
Changchun Institute of Biological Products Co., Ltd. CNBG	700,553
Adimmune Corporation	725,949
Becton Dickinson and Company (BD)	341,432
Institute of Virology, Vaccines and Sera Torlak	294,582
DiaSorin Molecular LLC (ex-Focus Diagnostic)	239,502
Beijing Tiantan Biological Products Co. Ltd.	235,234
Baxter International Inc.	209,238
Saint-Petersburg Scientific Research Institute of Vaccines & Sera	168,888
Alere Inc.	117,159
Takeda Pharmaceuticals Internatioanl GmbH	117,489
Zydus Cadila Healthcare Ltd.	102,108
Qiagen	61,512
CNBG- Wuhan Institute of Biological Products Co.,Ltd.	175,896
Beijing Bio-Institute biological Products Co. Ltd (BBIBP)	49,798
Serum Institute of India Ltd.	50,091
The Government Pharmaceutical Organization (GPO)	25,059
Cepheid	25,059
Institute of Vaccines and Medical Biologicals (IVAC)	25,059
Quidel Corporation	23,303
Princeton Biomeditech Corporation	23,303
China National Biotec Group	20,000
Indevr, Inc.	17,145
Response Biomedical Corporation	16,762
Vabiotech	15,230
Fast Track Diagnostics	13,045
NPO Petrovax Pharm	10,246
Medicago Inc.	7,439
Nanotherapeutics	5,337
Nanosphere Inc.	4,984
PT Bio Farma (Persero)	4,984
Protein Sciences Corporation	4,984
UMN Pharma Inc.	2,799
Lanzhou Institute of Biological Products	2,173
	\$ 354,774,734* (\$ 313,959,942 net of PSC)

*The figure does not include interest earned on Response Funds of ~\$18.7 million from 2018-2025.